drugset / Trial / NCT06264388
DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
Phase 2
Recruiting
33 enrolled
Ashish Shah
Denovo Biopharma LLC · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if the investigational products, DB107-RRV and DB107-FC, as a combination treatment will shrink high-grade glioma (HGG) in patients with recurrent/progressive, resectable or unresectable disease and increase the time that disease is controlled.
Timeline
- Start
- 2024-05-01
- Primary completion
- 2034-05-01
- Completion
- 2034-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Flucytosine | Small molecule | 220 mg/kg | Oral |
| Subject | Vocimagene Amiretrorepvec | Unknown | — | Intravenous |